A Study of Patients With AIDS Syndrome
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
AIDS-associated malignancy represents a model system for investigations of carcinogenesis. There are few human conditions in which cancer rates are of the magnitude they are in HIV infection. While studies have investigated pre-cancer markers in HIV-infected patients, they have not correlated these markers with tumor samples. This study contributes to understanding oncogenesis of HIV-associated malignancies by establishing a collection of tumors linked with pre-cancer sera and lymphocyte specimens, as well as prospective questionnaire data.
At study entry, patients receive a comprehensive ...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- You may be eligible for this trial if you:
- • Are HIV-positive.
- • Have a CD4+ cell count of 200 cells/mm3 or below.
- • Are 18 years of age or older.
- • Exclusion Criteria
- You will not be eligible for this trial if you:
- • Are not available for follow-up for at least 3 years.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Indianapolis, Indiana, United States
Columbus, Ohio, United States
San Francisco, California, United States
Seattle, Washington, United States
New York, New York, United States
Rochester, New York, United States
Chapel Hill, North Carolina, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Stanford, California, United States
Stanford, California, United States
Honolulu, Hawaii, United States
Baltimore, Maryland, United States
Buffalo, New York, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
New Orleans, Louisiana, United States
New Orleans, Louisiana, United States
New York, New York, United States
Boston, Massachusetts, United States
Menlo Park, California, United States
San Rafael, California, United States
Rochester, New York, United States
Patients applied
Trial Officials
David A. Wohl
Study Chair
Univ of North Carolina
Ann C. Collier
Study Chair
Univ of Washington
William G. Powderly
Study Chair
Charles S. Rabkin
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials